- My News
- All News
- Most Popular
Note: All changes are versus the prior-year period unless otherwise stated
CEO Karim Bitar remarked "we delivered a good trading performance in the third quarter. We continued to respond well to stronger-than- anticipated customer and patient demand, particularly in our infusion care and continence and critical care businesses." He added that "we now expect to deliver revenue growth at the higher end of our guidance range and to exceed our previous margin guidance for 2020."
ConvaTec said "we have revised our full-year constant currency revenue guidance and now expect to be towards the top end of the 2% to 3.5% growth range." The company also expects an adjusted earnings margin of between 18.5% and 19%, up from prior guidance of 16% to 18%. "We do not currently anticipate fourth-quarter year-on-year revenue growth due to the impact of the skincare business disposal, challenging 2019 comparatives coupled with the uncertainty arising from increasing COVID-19 infection rates," ConvaTec added.
To ensure you don't miss other Top Stories like these and news on key medtech industry developments, sign up for our free daily e-newsletter here.
Did you like this article?